
<DOC>
<DOCNO>WT03-B24-202</DOCNO>
<DOCOLDNO>IA064-000380-B023-126</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/library/corstr/costr.htm 206.86.52.80 19970112101922 text/html 3263
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:19:25 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3081
Last-modified: Fri, 11 Oct 1996 00:16:02 GMT
</DOCHDR>
<HTML>
<BODY background = "../../graphics/white-mi.gif">

<HEAD><TITLE> Corporate Strategies</TITLE></HEAD>



<H1><CENTER>Corporate Strategies</H1></CENTER><P>

Each of the following abstracts is linked directly to the complete English-language article.<P>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/032596a1.htm"> ReoPro marketing -- one year later </A></B><br>
This story discusses how hospitals have responded to Centocor Inc.'s anti-platelet antibody after a year of marketing by partner Eli Lilly. March 25, 1996 (3,400 words).<p>

<B><A HREF ="../../archive/1995/3qtr/0731a5.htm">Chuga's Worldwide Strategy</A></B><BR>

President Osamu Nagayama discusses Chugai‰s worldwide strategy. Chugai is the only Japanese company to own two U.S. biotech companies, Chugai Biopharmaceuticals (CBI) and Gen-Probe.  Nagayama explains Chugai‰s strategy to create a disease management company using CBI‰s therapeutic products and Gen-Probe‰s diagnostic and post-therapeutic monitoring products. (890 WORDS) An accompanying story describes the changing fortunes of the Japanese pharma markets (150 WORDS) 31.7.95 <P>

<B><A HREF="../../archive/1995/3qtr/0717a1.htm">Rebuilding Genentech</A></B><BR>

This story identifies two external fronts for CEO and President Arthur Levinson following the departure of G. Kirk Raab.  The first front is the perception that Roche Holdings wishes to turn GNE into an R&D affiliate from a fully integrated biopharmaceutical company. The second front is that the true cap on the common stock is $60, not the $82.50 call option held by Roche. GNE CFO Louis Lavigne is adamant that GNE will remain a fully integrated biopharmaceutical company. 17.7.95 (2750 WORDS)<P>

<B><A HREF="../../archive/1995/2qtr/0508b1.htm">biosys, the Consolidator</A></B><BR>

This story discusses efforts by biosys to consolidate biopesticide developers. BIOS‰s merger with AgriDyne Technologies Inc. follows its acquisition of Crop Genetics International. 8.5.95 (650 WORDS)<P>

<B><A HREF="../../archive/1995/1qtr/0327b1.htm">Pfizergen Network Takes Shape</A></B><BR>

Pfizergen is a network of strategic alliances announced by Pfizer Central Research.  Its purpose is to marry genetic research and biotechnology to traditional drug discovery methods. Pfizer currently has five strategic alliances with biotech companies and expects to announce more. 27.3.95 (750 WORDS)<P>

<h5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/homepg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>

</BODY></HTML>
</DOC>